Mabwell (Shanghai) Bioscience Management

Management criteria checks 2/4

Mabwell (Shanghai) Bioscience's CEO is Datao Liu, appointed in Jun 2020, has a tenure of 4.5 years. directly owns 3.78% of the company’s shares, worth CN¥317.10M. The average tenure of the management team and the board of directors is 4.5 years and 4.5 years respectively.

Key information

Datao Liu

Chief executive officer

CN¥2.4m

Total compensation

CEO salary percentage	n/a
CEO tenure	4.5yrs
CEO ownership	3.8%
Management average tenure	4.5yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO

Datao Liu (52 yo)

4.5yrs

Tenure

CN¥2,406,000

Compensation

Dr. Datao Liu serves as the General Manager and Director of Mabwell (Shanghai) Bioscience Co., Ltd. since June 2020 and serves as it Chief Executive Officer and has been its Chairman since June 2023. He al...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Datao Liu	Chairman	4.5yrs	CN¥2.41m	3.78% CN¥ 317.1m
Xin Du	Chief Scientific Officer & President of Maiwei (US)	4.5yrs	CN¥3.14m	no data
Yinhan Guo	Chief R&D Officer	4.2yrs	CN¥1.93m	no data
Jinchao Zhang	Deputy General Manager	4.5yrs	CN¥1.59m	1% CN¥ 84.0m
Huiguo Hu	Deputy GM	4.5yrs	CN¥1.58m	no data
Shu Hai Wang	Deputy General Manager	4.5yrs	CN¥1.58m	0.10% CN¥ 8.4m
Xi Chen	Deputy General Manager	3.9yrs	CN¥1.58m	no data
Han Li	Deputy General Manager	4.3yrs	CN¥1.94m	no data
Weiyi Dong	Deputy General Manager	4.5yrs	CN¥961.20k	no data
Hua Ni	Deputy General Manager	4.3yrs	CN¥1.42m	no data
Hai Wu	President of R&D	less than a year	no data	no data

4.5yrs

Average Tenure

52yo

Average Age

Experienced Management: 688062's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Datao Liu	Chairman	4.5yrs	CN¥2.41m	3.78% CN¥ 317.1m
Huiguo Hu	Deputy GM	3.6yrs	CN¥1.58m	no data
Chunshan Tang	Director	4.5yrs	no data	35.18% CN¥ 3.0b
Ning Xie	Director	4.5yrs	CN¥1.55m	1.64% CN¥ 138.0m
Bailing Li	Independent Director	4.2yrs	CN¥180.00k	no data
Qian Zhao	Independent Director	4.2yrs	CN¥180.00k	no data
Qing Xu	Independent Director	4.2yrs	CN¥180.00k	no data
Yongqi Guo	Director	4.5yrs	no data	no data
Jian Chu	Chairman of the Supervisory Board	4.5yrs	no data	no data
Xianghong Huang	Employee Representative Supervisor	4.5yrs	no data	no data
Yue Yin	Supervisor	4.5yrs	no data	no data

4.5yrs

Average Tenure

53yo

Average Age

Experienced Board: 688062's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 10:04
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mabwell (Shanghai) Bioscience Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yinhao Tang	Citic Securities Co., Ltd.
Shitong Han	Citic Securities Co., Ltd.
Jiabo Zhang	Guosen Securities Co., Ltd.

Mabwell (Shanghai) Bioscience Management

Management criteria checks 2/4

Key information

Recent management updates

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

New major risk - Share price stability

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA

New minor risk - Share price stability

FDA Grants Orphan Drug Designation to 7MW3711

FDA Grants Fast Track Designation to Mabwell's 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Mabwell Announces 9MW2821 Clinical Data

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821

First quarter 2024 earnings released: CN¥0.51 loss per share (vs CN¥0.60 loss in 1Q 2023)

Full year 2023 earnings released: CN¥2.64 loss per share (vs CN¥2.44 loss in FY 2022)

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting

Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Fiscal Year 2023 Results on Apr 09, 2024

National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA

Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial

Insufficient new directors

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

Second quarter 2023 earnings released: CN¥0.43 loss per share (vs CN¥0.51 loss in 2Q 2022)

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND

Full year 2022 earnings released: CN¥2.44 loss per share (vs CN¥2.57 loss in FY 2021)

High number of new and inexperienced directors

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources